annual EBITDA:
-$336.07M-$114.56M(-51.72%)Summary
- As of today (July 1, 2025), CRNX annual EBITDA is -$336.07 million, with the most recent change of -$114.56 million (-51.72%) on December 31, 2024.
- During the last 3 years, CRNX annual EBITDA has fallen by -$229.29 million (-214.73%).
- CRNX annual EBITDA is now -5580.68% below its all-time high of -$5.92 million, reached on December 31, 2016.
Performance
CRNX EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly EBITDA:
-$110.48M-$16.52M(-17.59%)Summary
- As of today (July 1, 2025), CRNX quarterly EBITDA is -$110.48 million, with the most recent change of -$16.52 million (-17.59%) on March 31, 2025.
- Over the past year, CRNX quarterly EBITDA has dropped by -$37.42 million (-51.23%).
- CRNX quarterly EBITDA is now -6719.75% below its all-time high of -$1.62 million, reached on June 30, 2017.
Performance
CRNX quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM EBITDA:
-$373.49M-$37.42M(-11.14%)Summary
- As of today (July 1, 2025), CRNX TTM EBITDA is -$373.49 million, with the most recent change of -$37.42 million (-11.14%) on March 31, 2025.
- Over the past year, CRNX TTM EBITDA has dropped by -$126.62 million (-51.29%).
- CRNX TTM EBITDA is now -14393.36% below its all-time high of -$2.58 million, reached on March 31, 2017.
Performance
CRNX TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
CRNX EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -51.7% | -51.2% | -51.3% |
| 3 y3 years | -214.7% | -228.9% | -217.4% |
| 5 y5 years | -534.8% | -529.6% | -481.6% |
CRNX EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -214.7% | at low | -157.9% | at low | -177.4% | at low |
| 5 y | 5-year | -534.8% | at low | -562.1% | at low | -481.6% | at low |
| alltime | all time | -5580.7% | at low | -6719.8% | at low | <-9999.0% | at low |
CRNX EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2025 | - | -$110.48M(+17.6%) | -$373.49M(+11.1%) |
| Dec 2024 | -$336.07M(+51.7%) | -$93.96M(+8.0%) | -$336.07M(+10.4%) |
| Sep 2024 | - | -$87.03M(+6.1%) | -$304.51M(+10.3%) |
| Jun 2024 | - | -$82.03M(+12.3%) | -$276.19M(+11.9%) |
| Mar 2024 | - | -$73.06M(+17.1%) | -$246.87M(+11.4%) |
| Dec 2023 | -$221.51M(+32.7%) | -$62.40M(+6.3%) | -$221.51M(+7.3%) |
| Sep 2023 | - | -$58.70M(+11.4%) | -$206.39M(+8.1%) |
| Jun 2023 | - | -$52.72M(+10.5%) | -$190.89M(+5.5%) |
| Mar 2023 | - | -$47.70M(+0.9%) | -$181.01M(+8.5%) |
| Dec 2022 | -$166.90M(+56.3%) | -$47.28M(+9.4%) | -$166.90M(+11.1%) |
| Sep 2022 | - | -$43.21M(+0.9%) | -$150.28M(+11.6%) |
| Jun 2022 | - | -$42.83M(+27.5%) | -$134.64M(+14.4%) |
| Mar 2022 | - | -$33.59M(+9.6%) | -$117.67M(+10.2%) |
| Dec 2021 | -$106.78M(+44.3%) | -$30.65M(+11.2%) | -$106.78M(+9.3%) |
| Sep 2021 | - | -$27.57M(+6.6%) | -$97.69M(+10.6%) |
| Jun 2021 | - | -$25.86M(+13.9%) | -$88.33M(+11.6%) |
| Mar 2021 | - | -$22.69M(+5.2%) | -$79.15M(+7.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2020 | -$74.00M(+39.8%) | -$21.57M(+18.4%) | -$74.00M(+9.8%) |
| Sep 2020 | - | -$18.21M(+9.1%) | -$67.42M(+5.0%) |
| Jun 2020 | - | -$16.68M(-4.9%) | -$64.22M(+5.9%) |
| Mar 2020 | - | -$17.55M(+17.1%) | -$60.65M(+14.5%) |
| Dec 2019 | -$52.95M(+87.5%) | -$14.98M(-0.1%) | -$52.95M(+12.2%) |
| Sep 2019 | - | -$15.00M(+14.4%) | -$47.18M(+17.6%) |
| Jun 2019 | - | -$13.12M(+33.2%) | -$40.11M(+23.0%) |
| Mar 2019 | - | -$9.84M(+6.7%) | -$32.60M(+15.5%) |
| Dec 2018 | -$28.24M(+213.8%) | -$9.22M(+16.3%) | -$28.24M(+31.6%) |
| Sep 2018 | - | -$7.93M(+41.4%) | -$21.47M(+35.1%) |
| Jun 2018 | - | -$5.61M(+2.4%) | -$15.89M(+33.5%) |
| Mar 2018 | - | -$5.48M(+123.6%) | -$11.90M(+32.2%) |
| Dec 2017 | -$9.00M(+52.1%) | -$2.45M(+4.2%) | -$9.00M(+37.4%) |
| Sep 2017 | - | -$2.35M(+45.2%) | -$6.55M(+56.0%) |
| Jun 2017 | - | -$1.62M(-37.1%) | -$4.20M(+62.9%) |
| Mar 2017 | - | -$2.58M | -$2.58M |
| Dec 2016 | -$5.92M | - | - |
FAQ
- What is Crinetics Pharmaceuticals annual EBITDA?
- What is the all time high annual EBITDA for Crinetics Pharmaceuticals?
- What is Crinetics Pharmaceuticals annual EBITDA year-on-year change?
- What is Crinetics Pharmaceuticals quarterly EBITDA?
- What is the all time high quarterly EBITDA for Crinetics Pharmaceuticals?
- What is Crinetics Pharmaceuticals quarterly EBITDA year-on-year change?
- What is Crinetics Pharmaceuticals TTM EBITDA?
- What is the all time high TTM EBITDA for Crinetics Pharmaceuticals?
- What is Crinetics Pharmaceuticals TTM EBITDA year-on-year change?
What is Crinetics Pharmaceuticals annual EBITDA?
The current annual EBITDA of CRNX is -$336.07M
What is the all time high annual EBITDA for Crinetics Pharmaceuticals?
Crinetics Pharmaceuticals all-time high annual EBITDA is -$5.92M
What is Crinetics Pharmaceuticals annual EBITDA year-on-year change?
Over the past year, CRNX annual EBITDA has changed by -$114.56M (-51.72%)
What is Crinetics Pharmaceuticals quarterly EBITDA?
The current quarterly EBITDA of CRNX is -$110.48M
What is the all time high quarterly EBITDA for Crinetics Pharmaceuticals?
Crinetics Pharmaceuticals all-time high quarterly EBITDA is -$1.62M
What is Crinetics Pharmaceuticals quarterly EBITDA year-on-year change?
Over the past year, CRNX quarterly EBITDA has changed by -$37.42M (-51.23%)
What is Crinetics Pharmaceuticals TTM EBITDA?
The current TTM EBITDA of CRNX is -$373.49M
What is the all time high TTM EBITDA for Crinetics Pharmaceuticals?
Crinetics Pharmaceuticals all-time high TTM EBITDA is -$2.58M
What is Crinetics Pharmaceuticals TTM EBITDA year-on-year change?
Over the past year, CRNX TTM EBITDA has changed by -$126.62M (-51.29%)